World Health Organization · 1st edition, 2025 · 48 pages
Evidence-based recommendations for treating uncomplicated liver and lung CE cysts, stratified by cyst stage, size and health facility capacity.
- Issuer
- World Health Organization
- Edition
- 1st edition, 2025
- Audience
- Clinicians, health facility managers, health practitioners at all service levels (primary, secondary, tertiary) and resource settings; NTD programme implementors, health policy-makers, health system administrators
- Evidence
- Seven conditional recommendations; all based on very low certainty evidence (GRADE) or expert consensus due to absence of comparative trials; evidence-to-decision frameworks for all PICO questions; health system tiers defined by expert consensus
- Reviewed
- 16 Oct 2026 · GMJ
What this guideline says
GMJ summary
The 2025 WHO guidelines provide the first comprehensive, tiered approach to treating cystic echinococcosis (CE), a parasitic disease caused by Echinococcus granulosus sensu lato that primarily affects the liver and lungs. The guidelines define four health system tiers based on available expertise and infrastructure, and match treatment options—albendazole (ALB) alone, percutaneous procedures (PAIR, standard catheterization), or surgery—to specific cyst stages (CE1–CE5) and sizes.
All seven recommendations are conditional with very low certainty evidence or expert consensus, reflecting the near-absence of comparative trials. For small active liver cysts ( 10 cm) are best treated with percutaneous methods, preferring PAIR over catheterization and surgery. Multivesicular cysts (CE2/CE3b) ≤ 5 cm may be tried on ALB initially, but those > 5 cm require surgery (open or laparoscopic) combined with ALB. Praziquantel is recommended post-procedure when spillage is suspected. Small lung cysts (≤ 5 cm) require surgery without pre-operative ALB.
The guidelines emphasize avoiding unnecessary invasive procedures where ALB alone may suffice, contraindicate PAIR when biliary communication is present, and call for 5-year imaging follow-up. They provide detailed dosing: ALB 10–15 mg/kg/day (up to 400 mg twice daily) for 3–6 months, with fat-rich meals; praziquantel 40–50 mg/kg/day for 2 weeks when spillage occurs. The recommendations are designed to ensure safe, resource-appropriate care across all income settings.
Key points
For clinicians — doses and thresholds as stated in the guideline
- Small active hepatic cysts CE1/CE3a < 5 cm: albendazole (ALB) 10–15 mg/kg/day (max 400 mg twice daily) for 3–6 months, applicable in any tier.
- Medium hepatic cysts CE1/CE3a 5–10 cm: PAIR combined with ALB (1–7 days pre-procedure, 1–3 months post-procedure), requires tier 3 or 4; PAIR contraindicated if biliary communication present.
- Large hepatic cysts CE1/CE3a > 10 cm: percutaneous treatment (PAIR preferred over standard catheterization or surgery) combined with ALB, requires tier 3 or 4.
- Small multivesicular hepatic cysts CE2/CE3b ≤ 5 cm: initial trial of ALB alone (any tier); escalate to surgery if no response at 3 months.
- Large multivesicular hepatic cysts CE2/CE3b > 5 cm: surgery (open or laparoscopic) combined with ALB; open surgery requires tier 2–4, laparoscopy tier 3–4.
- Praziquantel 40–50 mg/kg/day in two divided doses for 2 weeks post-procedure when spillage is suspected or has occurred, in addition to ALB.
- Uncomplicated lung CE cysts ≤ 5 cm: surgery without pre-operative ALB; ALB 1–3 months post-operatively if spillage suspected; requires tier 4 thoracic surgery capacity.
- Follow-up imaging at 3–6 months and annually for minimum 5 consecutive years after cyst inactivation; lack of response defined as no change after 3 months; complete response evaluated ≥ 12 months post-treatment.
Health care system tiers for managing CE treatment options
Table extracted from the guideline
| Tier | Health care worker expertise | Surgical infrastructure | Radiological capacity | Laboratory capacity | Interventions possible |
|---|---|---|---|---|---|
| Tier 1 | Medical doctor | Not available | Referral access to ultrasonography | Complete blood count, liver function tests | Albendazole |
| Tier 2 | General surgeon, Anaesthesiologist, Nursing care | Operating theatre, Inpatient facility with monitoring | Ultrasound on site | Laboratory tests as needed for anaesthesia | Tier 1 and Surgery (non-radical only) |
| Tier 3 (includes tier 2) | Surgeon with laparoscopic skills, Radiologist or physician trained in PAIR | General and laparoscopic surgery facilities, Inpatient facility with monitoring and ICU access | CT scan, Fluoroscopy | Laboratory tests as needed for anaesthesia | Tier 2 and Laparoscopic Surgery, PAIR, Standard catheterization |
| Tier 4 (includes tier 3) | General and laparoscopic surgeons, Interventional Radiologists, Thoracic Surgeon | Interventional Radiology Facilities and Procedure Room | MRI and MRCP | Routine clinical pathology, biochemistry and microbiology | Tier 3 and Modified Catheterization Technique, Thoracic (lung) surgery |
Source: World Health Organization, WHO guidelines for the treatment of patients with cystic echinococcosis. Reproduced in summary form.
From the guideline
Verbatim
“In patients with uncomplicated hepatic cyst types CE1 or CE3a < 5 cm, treatment with albendazole is suggested. This recommendation is applicable in any tier.”
Editor’s perspective
Why this matters for Georgia and the region
Prof. Giorgi Pkhakadze, MD, MPH, PhD
Editor-in-Chief, Georgian Medical Journal · Chair, Public Health Institute of Georgia · WHO consultant, health and migration
As Chair of the Public Health Institute of Georgia and a WHO consultant, I recognize that cystic echinococcosis remains a silent burden in our pastoral communities, often diagnosed late when cysts are large and complicated. These 2025 WHO guidelines offer Georgian clinicians a pragmatic, tiered roadmap that matches treatment intensity to cyst biology and local capacity: tier 1 primary care can confidently manage small active cysts with albendazole, sparing patients unnecessary referral and surgery, while tier 3 centres in Tbilisi and regional hubs can now standardize PAIR protocols with clear contraindications for biliary communication. I would stress to colleagues the critical importance of ultrasound staging before choosing intervention—misclassifying a CE2 multivesicular cyst as CE1 risks PAIR failure—and the mandate for 5-year imaging follow-up, which our national NTD programme must integrate into routine care. The caveat is that safe PAIR and laparoscopic surgery demand not only equipment (CT, fluoroscopy, laparoscopy towers) but sustained training and case volume; we must resist the temptation to offer these techniques in centres lacking experienced radiologists or surgeons, as complications—anaphylaxis from spillage, biliary fistula—can be catastrophic, and should instead establish referral pathways to accredited tier 3 and 4 facilities.
ORCID 0000-0001-7609-4515 · Perspective written for the GMJ Guidelines Library, 16 Oct 2026
Applicability
Georgia and the South Caucasus
Cystic echinococcosis remains endemic in Georgia and the South Caucasus, particularly in pastoral regions where sheep farming and close contact with shepherd dogs sustain transmission. National programmes must map existing tier capacity: many rural rayon hospitals can offer tier 1 ALB therapy and ultrasound screening, while tier 3 PAIR and laparoscopy are typically concentrated in Tbilisi and regional centres (Batumi, Kutaisi). Establishing safe PAIR services requires training radiologists or physicians, ensuring fluoroscopy and CT availability, and developing protocols to exclude biliary communication before injection of protoscolicidal agents. Tier 4 thoracic surgery and interventional radiology for complex cases may require cross-border referral networks within the Caucasus or to European centres. The guidelines’ tiered framework allows Georgia to allocate resources rationally: expand ALB availability and ultrasound-based ‘watch and wait’ in primary care, concentrate percutaneous and surgical expertise in tertiary centres, and integrate 5-year follow-up into the national imaging and NTD surveillance systems.
Questions this guideline answers
Quick answers
What is the treatment for a patient with a single 4 cm unilocular liver cyst (CE1) in a rural setting without surgical capacity?
Albendazole 10–15 mg/kg/day (up to 400 mg twice daily) given orally with a fat-rich meal, continuously for 3–6 months. This is tier 1-appropriate. Monitor liver enzymes and blood count for side-effects, and follow with ultrasound at 3–6 months and yearly for 5 years to confirm inactivation and detect recurrence.
When is PAIR contraindicated for an active hepatic CE cyst?
PAIR must not be used if biliary communication is present. During the procedure, if bile-stained cyst fluid is aspirated (check visually and for bilirubin) or if contrast injected into the cyst appears in the biliary tract, do not inject protoscolicidal agent. Alternative options include percutaneous drainage without injection (standard catheterization) plus prolonged ALB for 6 months, surgery, or medical management.
What is the role of praziquantel in CE treatment?
Praziquantel has protoscolicidal activity but does not kill the cyst. It is recommended at 40–50 mg/kg/day in two divided doses for 2 weeks after percutaneous or surgical procedures when spillage of cyst contents is suspected or has occurred, in addition to albendazole. It enhances albendazole sulfoxide levels and reduces risk of secondary dissemination.
Should albendazole be given before surgery for a 3 cm lung CE cyst?
No. For uncomplicated lung CE cysts ≤ 5 cm, albendazole should not be given before surgery due to perceived risk of rupture. Surgery is the recommended treatment. Give albendazole 10–15 mg/kg/day for 1–3 months post-operatively only if intraoperative spillage is suspected, and consider adding praziquantel for 2 weeks if spillage occurred.
Related on GMJ
Interconnected resources
Dictionary of Public Health
Conditions A–Z
GMJ News coverage
Quality & accreditation
Other guidelines on this topic
- Consolidated guidance on tuberculosis data generation and use: Module 4: Surveys of costs faced by households affected by tuberculosis
- Routine health information system and health facility data for neglected tropical diseases: general guidance for national programme managers and data clerks
- Routine health information system and health facility and community data for neglected tropical diseases: last-mile logistics information system for medicines and health products
- Routine health information system and health facility data for neglected tropical diseases: Buruli ulcer
- Social and behaviour change interventions for contraception and family planning
- Issuer
- World Health Organization
- Type
- Guideline
- Edition
- 1st edition, 2025
- Status
- Current
- Published
- 2025-06-17
- Languages
- English; Chinese, French, Russian and Spanish translations planned
- Scope
- Treatment of uncomplicated hepatic and pulmonary cystic echinococcosis in adults and children; excludes complicated cysts, inactive cysts (watch-and-wait approach described), alveolar echinococcosis, and bone/CNS locations
- Audience
- Clinicians, health facility managers, health practitioners at all service levels (primary, secondary, tertiary) and resource settings; NTD programme implementors, health policy-makers, health system administrators
- Pages
- 48
- Licence
- CC BY-NC-SA 3.0 IGO
- ISBN
- 978-92-4-011047-2
- Evidence
- Seven conditional recommendations; all based on very low certainty evidence (GRADE) or expert consensus due to absence of comparative trials; evidence-to-decision frameworks for all PICO questions; health system tiers defined by expert consensus
- Next review
- 7–10 years unless significant new evidence emerges earlier
- Record history
- Created 16 Oct 2026 · updated 16 Oct 2026 · next check Apr 2027
WHO guidelines for the treatment of patients with cystic echinococcosis. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.GMJ Guidelines Library records are original summaries written by the GMJ editorial team from the issuer’s published document and reviewed by a physician. They do not replace the full guideline. The document is the copyright of its issuer and is linked, not hosted. Spotted an error or a newer edition? Tell the Guidelines Desk.
Was this article helpful?
